Tissue Inhibitor of Matrix Metalloproteinase-2 in Nasopharyngeal Carcinoma

Amr Ahmed El Badry, MD; Amal Abou El-Fadle, MD; Abdel Latif El-Balshy, MD

Results

The study comprised 20 controls and 30 cases of NPC that were staged clinically according to TNM classification. Eight cases were diagnosed as stage II, 12 cases as stage III, and 10 cases as stage IV; however, histopathologic examination of biopsies taken revealed the presence of 9 specimens classified as WHO type I, 6 specimens classified as WHO type 2, and 15 specimens classified as WHO type 3 ( Table 1 ).

Figure 1 shows the percent positivity of TIMP-2 protein in malignant cases. Figure 2 illustrates the comparison between the patients with malignancies and the controls.

The difference in percentage of TIMP-2 positivity between NPC patients and controls was statistically highly significant ( Table 2 ), as determined by Chi-square test (x²). There was a significant positive correlation between TIMP-2 protein positivity and either the clinical staging or the histopathologic typing (P < .01) using Chi-square test (x²) ( Table 3 ).

(Enlarge Image)

Detection of TIMP-2 protein by Western blot in NPC patients (Lanes 2-8). TIMP-2 protein (21 KDa) was detected at the expected molecular weight (Lanes 2, 3, 5-8). Recombinant TIMP-2 protein positive control (Lane 1) and negative control for the immunodetection system (Lane 9) were included.

(Enlarge Image)

Detection of TIMP-2 protein by Western blot in NPC patients (Lane 2) and controls (Lanes 3-9). TIMP-2 protein (21 KDa) was detected at the expected molecular weight (Lanes 2, 5-7). Recombinant TIMP-2 protein (Lane 1) was included as a positive control.

1 2 3 4 5

Next Section

Cite this: Tissue Inhibitor of Matrix Metalloproteinase-2 in Nasopharyngeal Carcinoma - Medscape - Jul 03, 2007.

Clinical and Histopathologic Categorization of Nasopharyngeal Carcinoma Cases
Clinical Staging		Histopathologic Typing
Stage II	8 (26.7%)	WHO type 1	9 (30%)
Stage III	12 (40%)	WHO type 2	6 (30%)
Stage IV	10 (33.3%)	WHO type 3	51 (50%)

Stage II (T₂N₀M₀)
Stage III (T₃N₀M₀-T_1,2 or₃,N₁M₀)
Stage IV (T₄N₀M₀-any T,N₂ or N₃,.M₀-any T, any N,M₁)
T1: Tumor confined to 1 site or no tumor visible
T2: Involving 2 sites (both posterosuperior and lateral wall)
T3: Extension into nasal cavity or oropharynx
T4: Tumor invasion of skull or cranial nerve involvement (or both)
N1: Metastasis in a single ipsilateral lymph node < 3 cm
N2: Metastasis in contralateral, bilateral, multiple lymph nodes or > 3 cm but < 6 cm
N2: Metastasis in lymph nodes > 6 cm
M0: No distant metastasis
M1: Distant metastasis.
WHO type 1: Squamous cell carcinoma
WHO type 2: Nonkeratinizing carcinoma
WHO type 3: Undifferentiated carcinoma that is lymphoepithelioma and anaplastic carcinoma

Percent Positivity of TIMP-2 Protein: Comparison Between Nasopharyngeal Carcinoma Patients and Controls
Positivity of TIMP-2	Malignant Cases	Controls
	23/30	6/20
	76.6%	30%
Pearson's Chi-squared test (x²)	9.1
P-value	< .01*

*Highly significant

TIMP-2 Protein Positivity in Relation to Clinical Staging and Histopathologic Typing
TIMP-2	Histopathologic Typing				Clinical Staging
		Stage II	Stage III	Stage IV	WHO 1	WHO 2	WHO 3
	(-)	4	3	0	4	2	3
	(+)	4 (50%)	9 (75%)	10 (100%)	5 (44.4%)	3 (60%)	12 (80%)
Pearson's Chi-squared test (x²)	9.3				9.1
P* value	< .01				< .01

*P < .01 = highly significant

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Tissue Inhibitor of Matrix Metalloproteinase-2 in Nasopharyngeal Carcinoma

Results

Tables

Tables

Tables

References

Authors and Disclosures

Authors and Disclosures

Comments

Email This

Feedback